Cocrystal Pharma Stock Alpha and Beta Analysis
| COCP Stock | USD 1.10 0.01 0.92% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cocrystal Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cocrystal Pharma over a specified time horizon. Remember, high Cocrystal Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cocrystal Pharma's market risk premium analysis include:
Beta 1.2 | Alpha (0.17) | Risk 3.99 | Sharpe Ratio 0.0011 | Expected Return 0.0043 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cocrystal | Build AI portfolio with Cocrystal Stock |
Cocrystal Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cocrystal Pharma market risk premium is the additional return an investor will receive from holding Cocrystal Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cocrystal Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cocrystal Pharma's performance over market.| α | -0.17 | β | 1.20 |
Cocrystal Pharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cocrystal Pharma's Buy-and-hold return. Our buy-and-hold chart shows how Cocrystal Pharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cocrystal Pharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Cocrystal Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cocrystal Pharma shares will generate the highest return on investment. By understating and applying Cocrystal Pharma stock market price indicators, traders can identify Cocrystal Pharma position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Parabolic SAR | ||
| MidPoint over period | ||
| Hanging Man | ||
| Long Line Candle |
Cocrystal Pharma Return and Market Media
The median price of Cocrystal Pharma for the period between Fri, Oct 10, 2025 and Thu, Jan 8, 2026 is 1.05 with a coefficient of variation of 7.53. The daily time series for the period is distributed with a sample standard deviation of 0.08, arithmetic mean of 1.06, and mean deviation of 0.06. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Martin James Joseph of 7196 shares of Cocrystal Pharma at 1.24 subject to Rule 16b-3 | 10/28/2025 |
2 | Real time breakdown of Cocrystal Pharma Inc. stock performance - 2025 Dividend Review Weekly Top Performers Watchlists - newser.com | 10/29/2025 |
3 | Cocrystal Pharma reports Q3 EPS vs last year COCP | 11/14/2025 |
4 | Can Cocrystal Pharma Inc. stock sustain double digit ROE - Market Sentiment Summary Safe Entry Zone Tips - newser.com | 11/17/2025 |
5 | Can Cocrystal Pharma Inc. stock sustain double digit ROE - July 2025 PreEarnings Weekly Breakout Opportunity Watchlist - newser.com | 11/20/2025 |
6 | Acquisition by Martin James Joseph of 300000 shares of Cocrystal Pharma at 0.42 subject to Rule 16b-3 | 11/24/2025 |
7 | Acquisition by Frost Phillip Md Et Al of 20000 shares of Cocrystal Pharma at 0.9406 subject to Rule 16b-3 | 11/25/2025 |
8 | Acquisition by Frost Phillip Md Et Al of 1500 shares of Cocrystal Pharma at 1.0 subject to Rule 16b-3 | 11/26/2025 |
9 | Cocrystal Pharma to Present at the Noble Capital Markets 21st Emerging Growth Equity Conference | 12/01/2025 |
10 | Cocrystal Pharma Earnings Notes - Trefis | 12/15/2025 |
11 | Acquisition by Frost Phillip Md Et Al of 25000 shares of Cocrystal Pharma at 0.9703 subject to Rule 16b-3 | 12/24/2025 |
12 | Acquisition by Frost Phillip Md Et Al of 40000 shares of Cocrystal Pharma at 0.9736 subject to Rule 16b-3 | 12/26/2025 |
13 | Cocrystal Pharma Director Phillip Md Et Al Frost Buys 40,000 Shares | 12/29/2025 |
14 | Acquisition by Frost Phillip Md Et Al of 50000 shares of Cocrystal Pharma at 0.9455 subject to Rule 16b-3 | 12/31/2025 |
About Cocrystal Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cocrystal or other stocks. Alpha measures the amount that position in Cocrystal Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Payables Turnover | 0.094 | 0.0893 | Days Of Inventory On Hand | 101.98 | 69.1 |
Cocrystal Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Cocrystal Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cocrystal Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cocrystal Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cocrystal Pharma. Please utilize our Beneish M Score to check the likelihood of Cocrystal Pharma's management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cocrystal Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.